Sphera Funds Management LTD. raised its position in Cellectis S.A. (NASDAQ:CLLS) by 27.6% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 203,764 shares of the biotechnology company’s stock after buying an additional 44,100 shares during the period. Cellectis accounts for about 0.9% of Sphera Funds Management LTD.’s holdings, making the stock its 23rd largest position. Sphera Funds Management LTD. owned 0.58% of Cellectis worth $5,261,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Eqis Capital Management Inc. acquired a new position in shares of Cellectis during the first quarter worth approximately $202,000. Trexquant Investment LP acquired a new position in shares of Cellectis during the first quarter worth approximately $214,000. Finally, Vident Investment Advisory LLC boosted its position in shares of Cellectis by 20.0% in the first quarter. Vident Investment Advisory LLC now owns 50,994 shares of the biotechnology company’s stock worth $1,224,000 after buying an additional 8,496 shares during the last quarter. Institutional investors own 14.85% of the company’s stock.

Shares of Cellectis S.A. (NASDAQ:CLLS) traded up 11.89% during midday trading on Friday, reaching $32.18. 608,287 shares of the company’s stock were exchanged. Cellectis S.A. has a 12-month low of $16.09 and a 12-month high of $32.46. The stock’s 50 day moving average is $25.11 and its 200-day moving average is $24.03. The stock’s market cap is $1.15 billion.

ILLEGAL ACTIVITY WARNING: “Sphera Funds Management LTD. Has $5.26 Million Stake in Cellectis S.A. (CLLS)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/09/02/sphera-funds-management-ltd-has-5-26-million-stake-in-cellectis-s-a-clls.html.

A number of equities analysts recently commented on CLLS shares. Oppenheimer Holdings, Inc. set a $40.00 target price on shares of Cellectis and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a research report on Wednesday, July 19th. BidaskClub cut shares of Cellectis from a “buy” rating to a “hold” rating in a research report on Tuesday, July 25th. Finally, Jefferies Group LLC set a $47.00 target price on shares of Cellectis and gave the stock a “buy” rating in a research report on Friday, August 25th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $41.80.

About Cellectis

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis S.A. (NASDAQ:CLLS).

Institutional Ownership by Quarter for Cellectis (NASDAQ:CLLS)

Receive News & Stock Ratings for Cellectis S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis S.A. and related stocks with our FREE daily email newsletter.